Fig. 1 · Structure

Documents & Downloads

Quisinostat (JNJ-26481585)

Cat. No. A10492 CAS 875320-29-9

HDAC inhibitor

JNJ-26481585 (Quisinostat) is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC(50), 0.16 nmol/L).

In Stock

Publications for Quisinostat

1 publication citing this product

  1. Minoru Ueda, .et al. , Plant Physiol, 2017, Dec; 175(4): 1760-1773 PMID: 29018096

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HDAC1 IC50 0.11 nM
HDAC2 IC50 0.33 nM
HDAC11 IC50 0.37 nM
HDAC10 IC50 0.46 nM
HDAC5 IC50 3.69 nM
HDAC8 IC50 4.26 nM
HDAC3 IC50 4.86 nM
HDAC9 IC50 32.1 nM
HDAC6 IC50 76.8 nM
HDAC7 IC50 119 nM

10 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
D283 Med IC50 < 200 nM Antiproliferative activity against human D283 Med cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 33636537]
Daoy IC50 < 100 nM Antiproliferative activity against human Daoy cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 33636537]
HEK-293T IC50 0.06 μM Cytotoxicity against HEK293T cells incubated for 72 hrs by CCK-8 assay [PMID: 35175762]
HepG2 IC50 0.03 μM Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK-8 assay [PMID: 35175762]
HuT78 EC50 6.5 nM Pro-apoptotic activity in human HUT78 cells after 18 hrs by caspase-Glo 3/7 assay [PMID: 30122227]
Sf9 IC50 0.000617 μM Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay [PMID: 31938464]
Sf9 IC50 0.00196 μM Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay [PMID: 31938464]
Sf9 IC50 0.00216 μM Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay [PMID: 31938464]
Sf9 IC50 0.00404 μM Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay [PMID: 31938464]
Sf9 IC50 0.00461 μM Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay [PMID: 31938464]
Sf9 IC50 0.00595 μM Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay [PMID: 31938464]
Sf9 IC50 0.0067 μM Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay [PMID: 31938464]
Sf9 IC50 0.11 nM Inhibition of full length recombinant human HDAC1 expressed in baculovirus infected Sf9 cells using RHKK-Ac as substrate by fluorescence analysis [PMID: 27606546]
Sf9 IC50 0.33 nM Inhibition of full length recombinant human HDAC2 expressed in baculovirus infected Sf9 cells using RHKK-Ac as substrate by fluorescence analysis [PMID: 27606546]
Sf9 IC50 4.86 nM Inhibition of full length recombinant human HDAC3/NCOR2 expressed in baculovirus infected Sf9 cells using RHKK-Ac as substrate by fluorescence analysis [PMID: 27606546]
Sf9 IC50 76.8 nM Inhibition of full length recombinant human HDAC6 expressed in baculovirus infected Sf9 cells using RHKK-Ac as substrate by fluorescence analysis [PMID: 27606546]

16 records · Scroll to view more

Quisinostat (JNJ-26481585) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Quisinostat (JNJ-26481585) from 3 published references. In vitro models include A549 cells; HCC1569 cells.

Quisinostat (JNJ-26481585) In Vitro Studies

In A549 cells, Quisinostat treatment yielded cell viability IC50 values of 82.4 and 42.0 nM after 48 and 72 h, respectively, and reduced migrating-cell measurements relative to control cells. In HCC1569 cells, Quisinostat induced detectable gene expression changes by 30 min, followed by a progressive increase in differentially expressed genes over time. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell viability in lung cancer cells

Cell-based study · A549 cells [1]

A549 cells were treated with Quisinostat and assessed for cell viability. After 48 and 72 h of treatment, IC50 values were 82.4 and 42.0 nM, respectively.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityIC50 the IC50 values of cells for 48 and 72 h of quisinostat treatment were 82.4 and 42.0 nM, respectively[1]

Literature-Reported Treatment Conditions

Treatment concentration
5, 10, 20, 40, 60, 80, 100, 125, 250, and 500 nM
Exposure duration
24, 48, or 72 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Quisinostat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Quisinostat inhibited the viability of A549 cells (S50, S51, S52, S53)

cell viability: cell viability; comparator: control cells — Results > Quisinostat inhibited the viability of A549 cells (S50, S53)

Gene expression changes in HCC1569 cells

Cell-based study · HCC1569 cells [2]

HCC1569 cells were treated with 100 nM Quisinostat and assessed by RNA-seq analysis. Detectable gene expression changes appeared by 30 min, with the number of differentially expressed genes increasing progressively over time.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RNA-seq analysisdifferentially expressed genes uninduced Quisinostat-treated cells; 100 nM Quisinostat: ~10,000 differentially expressed genes (DEGs) by 10 h[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
30 min, 1 h, 3 h and 10 h of treatment
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Quisinostat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Self-renewal-associated oncogenic pathways regulated by H1.0 (S71, S72, S73); Methods > RNA sequencing and quantitative RT-PCR (S267, S276, S277)

RNA-seq analysis: RNA-seq analysis; comparator: DMSO-treated control cells — Results > Self-renewal-associated oncogenic pathways regulated by H1.0 (S71, S73); Methods > RNA sequencing and quantitative RT-PCR (S267, S277)

Migration in lung cancer cells

Cell-based study · A549 cells [1]

A549 cells were treated with Quisinostat for 24 h. Migrating cells decreased relative to control group cells across the tested concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
OD values of crystal violetcell migration 88.30 ± 4.02, 68.97 ± 2.68, and 55.50 ± 4.33 % of control group cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
25, 50, and 100 nM
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Quisinostat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Quisinostat inhibited A549 cell migration by suppressing EMT process (S72, S73)

OD values of crystal violet: OD values of crystal violet; comparator: control group cells — Results > Quisinostat inhibited A549 cell migration by suppressing EMT process (S73)

Quisinostat (JNJ-26481585) In Vivo Studies

Male nude athymic mice bearing HCCLM3 xenografts received Quisinostat by intraperitoneal injection at 10 mg/kg. Both Quisinostat and sorafenib alone markedly repressed tumor growth compared with the control group. [3]

Tumor growth in a xenograft model

Animal study · Male nude athymic mice; HCCLM3 xenograft model; n = 7 [3]

Male nude athymic mice bearing HCCLM3 xenografts received Quisinostat by intraperitoneal injection at 10 mg/kg. Both Quisinostat and sorafenib alone markedly repressed tumor growth compared with the control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor volumeReported result both quisinostat and sorafenib alone markedly repressed tumor growth of HCCLM3 cells in vivo compared with control group[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
five times per week for 4 weeks
Vehicle
5% [v/v] DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Quisinostat 10 mg/kgvehicle (5% [v/v] DMSO)both quisinostat and sorafenib alone markedly repressed tumor growth of HCCLM3 cells in vivo compared with control group[3]
Quisinostat 10 mg/kg
Model: Male nude athymic mice; HCCLM3 xenograft model; n = 7
Methods and source locations

Compound reported in the paper: Quisinostat

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Xenograft model analysis (S47, S48, S49, S50, S51, S52); Results > The combination of Quisinostat and Sorafenib inhibited tumor growth in a HCCLM3 xenograft model (S118); Figure 7 legend (S171, S172, S173)

tumor volume: tumor volume; comparator: vehicle (5% [v/v] DMSO) — Materials and methods > Xenograft model analysis (S52); Results > The combination of Quisinostat and Sorafenib inhibited tumor growth in a HCCLM3 xenograft model (S118)

Quisinostat 10 mg/kg · Materials and methods > Xenograft model analysis (S50, S51); Results > The combination of Quisinostat and Sorafenib inhibited tumor growth in a HCCLM3 xenograft model (S118)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 875320-29-9
Applications HDAC inhibitor
Formula C21H26N6O2
Molecular Weight 394.5
Synonyms JNJ-26481585
SMILES
CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Quisinostat (JNJ-26481585) Research References

  1. [1] Bao L, Diao H, Dong N, et al. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol Toxicol (2016). PMID: 27423454 DOI: 10.1007/s10565-016-9347-8 Source material
  2. [2] Morales Torres C, Wu MY, Hobor S, et al. Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. Nat Commun (2020). PMID: 32286289 DOI: 10.1038/s41467-020-15615-z Source material
  3. [3] He B, Dai L, Zhang X, et al. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction. Int J Biol Sci (2018). PMID: 30443188 DOI: 10.7150/ijbs.27661 Source material

Publications

1 publication citing this product

  1. Minoru Ueda, .et al. , Plant Physiol, 2017, Dec; 175(4): 1760-1773 PMID: 29018096

Added to your cart

View Cart Checkout
Loading...